Brief: Psyence Group Receives Mid-Stage Study Approval From UK Health Regulator
19/09/2022 12:11
Sept 19 (Reuters) - Psyence Group Inc PSYG.CD :
* PSYENCE GROUP RECEIVES PHASE IIA CLINICAL TRIAL APPROVAL
FROM
THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
(MHRA)
* PSYENCE GROUP RECEIVES PHASE IIA CLINICAL TRIAL APPROVAL
FROM
THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
(MHRA)
Source text for Eikon: ID:nGNXnd5rt
Further company coverage: PSYG.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Psyence
See all newsBrief: Psyence Group To Consolidate Shares 15 To 1 Effective April 23, 2025
Brief: Psyence Group Enters Into Debt-For-Equity Swap Agreement With Its Nasdaq-Listed Associate, Psyence Biomedical
Brief: Psyence Biomed Enters Into Agreement To Acquire Stake In Psylabs
Brief: Psyence Biomedical Ltd. Approved To List On Nasdaq Following Completion Of Business Combination Agreement With Newcourt Acquisition Corp
MGC Pharmaceuticals - September 2023 Quarter Activity Report